resTORbio Company
Clinical-stage biopharma company spun out from Novartis in 2016, headquartered in Boston, Massachusetts. resTORbio develops therapeutics targeting the mTOR pathway to improve immune function and resilience in older adults. Lead programs address immunosenescence and age-related conditions, with the goal of enhancing healthspan by modulating pathways of cellular growth and metabolism. (restorbio.com)
Investors
%20.jpg)
Founded Date:
2016
Estimated Revenue:
No public info
Number Of Exists:
Series B
Headquarters:
500 Boylston Street in Boston, Massachusetts